3BP and Novartis strike licensing agreement for FAP-targeting peptide technology

25 Apr 2023
www.pharmaceutical-technology.com
License out/inPhase 1PDC
3BP and Novartis strike licensing agreement for FAP-targeting peptide technology
Preview
Source: Pharmaceutical Technology
3B Pharmaceuticals (3BP) is a German biotechnology company developing radiopharmaceutical drugs and diagnostics for oncology indications. Credit: stevepb from Pixabay.
German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology.
The deal provides Novartis with exclusive rights across the globe to create and commercialise therapeutic and imaging solutions for 3BP’s entire FAP-targeting peptide technology, including FAP-2286.
Recommended Reports
3BP and Novartis strike licensing agreement for FAP-targeting peptide technology
Preview
Source: Pharmaceutical Technology
3BP and Novartis strike licensing agreement for FAP-targeting peptide technology
Preview
Source: Pharmaceutical Technology
ReportsClostridium difficile Toxin B (toxB or EC 3.4.22.) Drugs in Development by Therapy Areas and Indi... GlobalData
View all
3BP receives an initial payment of $40m, and $425m as development, regulatory and commercial milestone payments. Tiered royalties on net sales are also included in the deal.
3BP continues to hold specific rights to develop its FAP-targeting imaging technology for diagnostic applications.
FAP-2286 is being investigated as a peptide-targeted radionuclide therapy. It is capable of targeting FAP, a significant theranostic target with expression across various types of cancers.
FAP-2286 marks the first peptide-targeted radioligand therapy aiming at FAP to enter clinical development, along with the respective imaging agent.
The therapy candidate is currently under evaluation in the Phase l LuMIERE clinical trial.
3BP nuclear medicine and imaging head Dr Christiane Smerling stated: “We believe the new agreement with Novartis is an ideal partnership for the further clinical development of FAP-2286 for the benefit of patients with many different types of cancer.”
In 2019, 3BP reached a licence and collaboration deal with Clovis Oncology to support the development of a peptide-targeted radiotherapy and imaging agent targeting FAP.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.